Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Opioid-Related Disorders 1Neoplasms 1Constipation 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × methylnaltrexone × Clear all
NCT06162377 2025-12-17

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

M.D. Anderson Cancer Center

Phase 4 Recruiting
25 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01004393 2016-02-02

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

University of Vermont

Phase 2 Completed
12 enrolled 10 charts
Other

Constipation, Opioid-Related Disorders, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡